Holen Sie sich die Stockscreener-App
0.216
19.99%
0.0309
Sangamo Therapeutics Inc Aktie (SGMO) Neueste Nachrichten
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Davis Gregory D - Moomoo
Sangamo (SGMO) executive shares withheld to cover RSU tax obligations - Stock Titan
Sangamo (SGMO) SVP surrenders 4,036 shares for RSU tax withholding - Stock Titan
Sangamo (SGMO) SVP uses 4,036 shares to cover RSU tax - Stock Titan
Sangamo Therapeutics (SGMO) CEO surrenders RSU shares to cover taxes - Stock Titan
Sangamo presents primate data for prion suppressor ST-506 - BioWorld News
Sangamo Therapeutics (SGMO) reports Q1 loss, misses revenue estimates - MSN
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2026 Earnings Call Transcript - Insider Monkey
Sangamo Therapeutics Reports No Unregistered Equity Sales or Share Repurchases for the Period - TipRanks
Sangamo Therapeutics, Inc. (SGMO) Presents at 29th ASGCT Annual Meeting 2026Slideshow - Seeking Alpha
Finance Watch: Sangamo Once Again Nearing The End Of Its Cash - Citeline News & Insights
Sangamo Therapeutics | SCHEDULE 13G: Others - Moomoo
Sangamo Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (OTCMKTS:SGMO) 2026-05-15 - Seeking Alpha
Q1 2026 Sangamo Therapeutics Inc Earnings Call Transcript - GuruFocus
Sangamo Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Sangamo Therapeutics (SGMO) Q1 2026 Earnings: EPS -$0.08 vs $0.0 - GuruFocus
Sangamo Therapeutics (SGMO) Advances BLA Submission Amid OTCQB T - GuruFocus
Sangamo Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Sangamo Therapeutics Inc (SGMO) Q1 2026 Earnings Call Highlights: Progress Amidst Financial Challenges - GuruFocus
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Sangamo anticipates completing ST-920 BLA submission as early as this summer while appealing NASDAQ delisting in June - MSN
Sangamo Therapeutics earnings missed by $0.02, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Sangamo Therapeutics Q1 2026 reveals financial challenges - Investing.com Nigeria
SGMO: BLA submission for Fabry therapy advances as FDA waives need for a second confirmatory study - TradingView
SGMO: Advanced BLA submission for Fabry therapy, FDA support, and strategic capital efforts underway - TradingView
Transcript : Sangamo Therapeutics, Inc., Q1 2026 Earnings Call, May 14, 2026 - marketscreener.com
Sangamo Therapeutics | 8-K: SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2026 FINANCIAL RESULTS - Moomoo
Full Transcript: Sangamo Therapeutics Q1 2026 Earnings Call - Benzinga
Press Release: Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results - Moomoo
Sangamo Therapeutics Inc (NASDAQ:SGMO) Misses Q1 2026 Estimates, Stock Plunges 15.6% - ChartMill
SANGAMO THERAPEUTICS ($SGMO) Releases Q1 2026 Earnings - Quiver Quantitative
More on Sangamo Therapeutics - MSN
Sangamo Therapeutics Q1 2026 earnings preview - MSN
Sangamo: Q1 Earnings Snapshot - Barchart.com
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results - The Manila Times
Sangamo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Sangamo Therapeutics reports Q1 2026 net loss of $31.0M; revenues $1.4M, cash $27.6M - TradingView
TradingKey - TradingKey
Sangamo Therapeutics : Zinc finger fusions and synthetic DNA donor engineering improve the performance of reprogrammed modular integrases at the TRAC locus - marketscreener.com
Sangamo Therapeutics Announces First Quarter 2026 Earnings Call - The Manila Times
Sangamo Therapeutics (SGMO) Eps Diluted (TTM) - Zacks Investment Research
Sangamo Therapeutics, Inc.(OTCPK: SGMO) dropped from S&P TMI Index - marketscreener.com
Sangamo Therapeutics, Inc.(OTCPK: SGMO) dropped from S&P Global BMI Index - marketscreener.com
SGMO Price Today: Sangamo Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
SGMO Stock Could Be Ready for a Major Rebound as Investor Interest Grows - vocal.media
SGMO ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Sangamo Therapeutics, Inc. Shareholders Who Lost Money - ACCESS Newswire
Sangamo Therapeutics(SGMO) Stock Options Chain | Quotes & News - Moomoo
Free cash flow of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
CapEx per share of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Basic earnings per share (basic EPS) of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Gross margin % of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Tangible book value per share of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Non-controlling/minority interest of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Cash from investing activities of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
0.48%
0.73%
Kapitalisierung:
|
Volumen (24h):